Hertz, D. L., Smith, K. L., Zong, Y., Gersch, C. L., Pesch, A. M., Lehman, J., . . . Stearns, V. (2021). Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. Front Genet.
Chicago Stili AlıntıHertz, Daniel L., et al. "Further Evidence That OPG Rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer." Front Genet 2021.
MLA AlıntıHertz, Daniel L., et al. "Further Evidence That OPG Rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer." Front Genet 2021.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..